Prosecution Insights
Last updated: April 19, 2026
Application No. 19/215,242

COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL

Final Rejection §103§DP
Filed
May 21, 2025
Examiner
HENLEY III, RAYMOND J
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
VERADERMICS INCORPORATED
OA Round
2 (Final)
83%
Grant Probability
Favorable
3-4
OA Rounds
2y 0m
To Grant
86%
With Interview

Examiner Intelligence

Grants 83% — above average
83%
Career Allow Rate
1041 granted / 1248 resolved
+23.4% vs TC avg
Minimal +2% lift
Without
With
+2.1%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
31 currently pending
Career history
1279
Total Applications
across all art units

Statute-Specific Performance

§101
4.0%
-36.0% vs TC avg
§103
19.4%
-20.6% vs TC avg
§102
10.0%
-30.0% vs TC avg
§112
30.1%
-9.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1248 resolved cases

Office Action

§103 §DP
CLAIMS 1-21 ARE PRESENTED FOR EXAMINATION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s Amendment/remarks filed February 12, 2026 have been received and entered into the application. In light thereof, the rejection of the claims under 35 USC 103, as set forth in the previous Office action, has been overcome and is hereby withdrawn. Double Patenting Applicant has deferred responding to the rejections below. Both double patenting rejections are deemed to remain proper for the reasons set forth in the previous Office action, which reasons are here incorporated by reference. Provisional Claims 1-21 remain provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20, (unless otherwise specified), of copending Application Nos. (reference applications).19/094,716; 19/253,703; 19/253,708; 19/255,878; 19/230,047, (claims 1-21); 19/230,054, (claims 1-21); 19/258,817; 19/260,035; 19/267,447; 19/267,464; 19/308,124; 19/315,454, (claims 1-19); 19/328,077, (claims 1-19); or 19/329,494, (claims 1-19). This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Non-Provisional Claims 1-21 remain rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-28 of U.S. Patent No. 12,268,688, (cited by Applicant) or (b) claims 1-20 of U.S. Patent No. 12,491,184, (cited by the Examiner). Accordingly, the claims are deemed properly rejected and none are currently in condition for allowance. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RAYMOND J HENLEY III whose telephone number is (571)272-0575. The examiner can normally be reached M-F 6-2:30pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey S Lundgren can be reached on 571-272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RAYMOND J HENLEY III/Primary Examiner, Art Unit 1629 March 26, 2026
Read full office action

Prosecution Timeline

May 21, 2025
Application Filed
Jan 12, 2026
Non-Final Rejection — §103, §DP
Feb 09, 2026
Interview Requested
Feb 12, 2026
Response Filed
Feb 12, 2026
Interview Requested
Feb 25, 2026
Applicant Interview (Telephonic)
Feb 25, 2026
Examiner Interview Summary
Mar 26, 2026
Final Rejection — §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599604
APPLICATION OF JAK INHIBITOR IN KIDNEY DISEASE
2y 5m to grant Granted Apr 14, 2026
Patent 12594278
METHOD FOR TREATMENT OF MUSCULAR DYSTROPHY
2y 5m to grant Granted Apr 07, 2026
Patent 12595269
BRIDGED RING COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTS
2y 5m to grant Granted Apr 07, 2026
Patent 12589097
APILIMOD COMPOSITIONS AND METHODS OF USE
2y 5m to grant Granted Mar 31, 2026
Patent 12582631
METHODS OF IMPROVING RENAL FUNCTION
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
83%
Grant Probability
86%
With Interview (+2.1%)
2y 0m
Median Time to Grant
Moderate
PTA Risk
Based on 1248 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month